Waltham, Massachusetts, United States, November 2024 – Rebecca R. Lora has joined Mural Oncology as the Director, Talent and Team. In her new role, Rebecca will lead initiatives aimed at driving organizational growth, talent acquisition, and team development. With a deep understanding of human resources strategies and a track record of success in the pharmaceutical and biotechnology sectors, she is set to play a pivotal role in shaping Mural Oncology’s workforce strategies.
Rebecca’s extensive experience spans over 15 years in human resources and organizational leadership. Prior to joining Mural Oncology, she held the position of Associate Director, Human Resources at ROME Therapeutics, where she collaborated with senior leaders to implement effective organizational design, talent management, and development strategies. She also served as Senior Manager, Human Resources, during her tenure at the organization, contributing to impactful HR initiatives.
Before ROME Therapeutics, Rebecca spent over six years at Agios Pharmaceuticals, where she rose through the ranks from Executive Assistant to Manager, Talent Acquisition. Her contributions included partnering with senior business leaders across functions to drive end-to-end recruitment and delivering strategic hiring solutions.
Rebecca also has notable experience at Pfizer, where she served as Executive Assistant to the Chief Scientific Officer, Immunoscience Research Unit, and at The Rockefeller University, where she managed administrative operations for a prominent immunology research laboratory.
Mural Oncology is at the forefront of revolutionizing cytokine-based immunotherapies for cancer treatment. Guided by a mission to transform overlooked opportunities in cancer drug development, the company combines technical precision with creativity and innovation to develop groundbreaking immunotherapies.
Leveraging an advanced protein engineering platform, Mural Oncology aims to address unmet needs in cancer care, offering hope to patients who have not benefited from existing therapies. With expertise in cytokine biology and immune cell modulation, the company is building a portfolio of novel immunotherapies designed to provide meaningful clinical benefits across diverse cancer types.
As a publicly traded company (NASDAQ: MURA), Mural Oncology continues to innovate, delivering on its promise to change lives through transformative cancer treatments.
Click Here to Join HR TODAY WhatsApp Channel
Read Also : People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
